{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:42:54Z","timestamp":1791333774810,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]},{"name":"Secretar\u00eda de Educaci\u00f3n, Ciencia, Tecnolog\u00eda e Innovaci\u00f3n de la Ciudad de M\u00e9xico","award":["SECTEI\/061\/2023"],"award-info":[{"award-number":["SECTEI\/061\/2023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12331-w","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:16:42Z","timestamp":1753273002000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edema"],"prefix":"10.1038","volume":"15","author":[{"given":"Elva","family":"Ad\u00e1n-Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Granados-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Siqueiros-M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose F.","family":"Garc\u00eda-Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Triebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Mart\u00ednez de la Escalera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"12331_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000438970","volume":"55","author":"SR Cohen","year":"2016","unstructured":"Cohen, S. R. & Gardner, T. W. Diabetic retinopathy and diabetic macular edema. Dev. Ophthalmol. 55, 137\u2013146 (2016).","journal-title":"Dev. Ophthalmol."},{"key":"12331_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","volume":"142","author":"QD Nguyen","year":"2006","unstructured":"Nguyen, Q. D. et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am. J. Ophthalmol. 142, 961\u2013969 (2006).","journal-title":"Am. J. Ophthalmol."},{"key":"12331_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/ICU.0000000000000424","volume":"28","author":"S Cai","year":"2017","unstructured":"Cai, S. & Bressler, N. M. Aflibercept, bevacizumab or Ranibizumab for diabetic macular oedema: recent clinically relevant findings from drcr.net protocol T. Curr. Opin. Ophthalmol. 28, 636\u2013643 (2017).","journal-title":"Curr. Opin. Ophthalmol."},{"key":"12331_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani, K. G. & Nguyen, Q. D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 27, 787\u2013794 (2013).","journal-title":"Eye"},{"key":"12331_CR5","doi-asserted-by":"publisher","first-page":"35470","DOI":"10.1021\/acsomega.3c02897","volume":"8","author":"SHS Boddu","year":"2023","unstructured":"Boddu, S. H. S. et al. An update on strategies to deliver protein and peptide drugs to the eye. ACS Omega. 8, 35470\u201335498 (2023).","journal-title":"ACS Omega"},{"key":"12331_CR6","doi-asserted-by":"crossref","unstructured":"del Amo, E. M. Topical ophthalmic administration: can a drug instilled onto the ocular surface exert an effect at the back of the eye? Front Drug Deliv 2, (2022).","DOI":"10.3389\/fddev.2022.954771"},{"key":"12331_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/978-3-319-12114-7_4","volume":"846","author":"C Clapp","year":"2015","unstructured":"Clapp, C. et al. Regulation of blood vessels by prolactin and vasoinhibins. Adv. Exp. Med. Biol. 846, 83\u201395 (2015).","journal-title":"Adv. Exp. Med. Biol."},{"key":"12331_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10456-021-09800-x","volume":"25","author":"JP Robles","year":"2022","unstructured":"Robles, J. P. et al. The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide. Angiogenesis 25, 57\u201370 (2022).","journal-title":"Angiogenesis"},{"key":"12331_CR9","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1167\/iovs.05-0173","volume":"46","author":"J Aranda","year":"2005","unstructured":"Aranda, J. et al. Prolactins are natural inhibitors of angiogenesis in the retina. Invest. Ophthalmol. Vis. Sci. 46, 2947\u20132953 (2005).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR10","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1167\/iovs.03-1001","volume":"45","author":"H Pan","year":"2004","unstructured":"Pan, H. et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest. Ophthalmol. Vis. Sci. 45, 2413\u20132419 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/labinvest.2015.135","volume":"96","author":"N Diaz-Lezama","year":"2016","unstructured":"Diaz-Lezama, N. et al. Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab. Invest. 96, 283\u2013295 (2016).","journal-title":"Lab. Invest."},{"key":"12331_CR12","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1167\/iovs.03-1346","volume":"45","author":"Z Duenas","year":"2004","unstructured":"Duenas, Z. et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest. Ophthalmol. Vis. Sci. 45, 2049\u20132055 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/pr.2016.241","volume":"81","author":"LC Zepeda-Romero","year":"2017","unstructured":"Zepeda-Romero, L. C. et al. Higher prolactin and vasoinhibin serum levels associated with incidence and progression of retinopathy of prematurity. Pediatr. Res. 81, 473\u2013479 (2017).","journal-title":"Pediatr. Res."},{"key":"12331_CR14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1530\/EJE-09-0130","volume":"161","author":"J Triebel","year":"2009","unstructured":"Triebel, J., Huefner, M. & Ramadori, G. Investigation of prolactin-related vasoinhibin in Sera from patients with diabetic retinopathy. Eur. J. Endocrinol. 161, 345\u2013353 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"12331_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1167\/tvst.9.9.27","volume":"9","author":"CD Nu\u00f1ez-Amaro","year":"2020","unstructured":"Nu\u00f1ez-Amaro, C. D. et al. Levosulpiride increases the levels of prolactin and antiangiogenic vasoinhibin in the vitreous of patients with proliferative diabetic retinopathy. Transl Vis. Sci. Technol. 9, 27\u201327 (2020).","journal-title":"Transl Vis. Sci. Technol."},{"key":"12331_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02715-5","author":"CD N\u00fa\u00f1ez-Amaro","year":"2023","unstructured":"N\u00fa\u00f1ez-Amaro, C. D. et al. Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial. Eye (Lond). 38, 520-528 (2024).","journal-title":"Eye (Lond)"},{"key":"12331_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pep.2019.04.011","volume":"161","author":"B Moreno-Carranza","year":"2019","unstructured":"Moreno-Carranza, B. et al. Sequence optimization and glycosylation of vasoinhibin: pitfalls of Recombinant production. Protein Expr Purif. 161, 49\u201356 (2019).","journal-title":"Protein Expr Purif."},{"key":"12331_CR18","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/S1046-5928(02)00639-3","volume":"28","author":"M Galfione","year":"2003","unstructured":"Galfione, M. et al. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif. 28, 252\u2013258 (2003).","journal-title":"Protein Expr Purif."},{"key":"12331_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nprot.2007.54","volume":"2","author":"B Baudin","year":"2007","unstructured":"Baudin, B., Bruneel, A., Bosselut, N. & Vaubourdolle, M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat. Protoc. 2, 481\u2013485 (2007).","journal-title":"Nat. Protoc."},{"key":"12331_CR20","doi-asserted-by":"publisher","first-page":"1345996","DOI":"10.3389\/fendo.2024.1345996","volume":"15","author":"M Zamora","year":"2024","unstructured":"Zamora, M. et al. Immunometric and functional measurement of endogenous vasoinhibin in human Sera. Front. Endocrinol. (Lausanne). 15, 1345996 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"12331_CR21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3390\/pharmaceutics11120638","volume":"11","author":"AB S\u00e1nchez","year":"2019","unstructured":"S\u00e1nchez, A. B., Calpena, A. C., Mallandrich, M. & Clares, B. Validation of an ex vivo permeation method for the intestinal permeability of different BCS drugs and its correlation with Caco-2 in vitro experiments. Pharmaceutics 11, 638 (2019).","journal-title":"Pharmaceutics"},{"key":"12331_CR22","doi-asserted-by":"publisher","first-page":"e13091","DOI":"10.1111\/jne.13091","volume":"34","author":"E Ad\u00e1n-Castro","year":"2022","unstructured":"Ad\u00e1n-Castro, E. et al. Sulpiride-induced hyperprolactinaemia increases retinal vasoinhibin and protects against diabetic retinopathy in rats. J. Neuroendocrinol. 34, e13091 (2022).","journal-title":"J. Neuroendocrinol."},{"key":"12331_CR23","doi-asserted-by":"publisher","first-page":"619696","DOI":"10.3389\/fendo.2021.619696","volume":"12","author":"G Ramirez-Hernandez","year":"2021","unstructured":"Ramirez-Hernandez, G. et al. Global deletion of the prolactin receptor aggravates Streptozotocin-Induced diabetes in mice. Front. Endocrinol. (Lausanne). 12, 619696 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"12331_CR24","doi-asserted-by":"publisher","first-page":"8944","DOI":"10.1167\/iovs.11-8190","volume":"52","author":"M Ram\u00edrez","year":"2011","unstructured":"Ram\u00edrez, M. et al. Vasoinhibin gene transfer by adenoassociated virus type 2 protects against VEGF- and diabetes-induced retinal vasopermeability. Invest. Ophthalmol. Vis. Sci. 52, 8944\u20138950 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR25","unstructured":"Dash Gallery. Plotly: Noncompartmental Pharmacokinetics Analysis. (2021)."},{"key":"12331_CR26","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.3390\/ijms22157836","volume":"22","author":"VB Dugina","year":"2021","unstructured":"Dugina, V. B., Shagieva, G. S., Shakhov, A. S. & Alieva, I. B. The cytoplasmic actins in the regulation of endothelial cell function. Int. J. Mol. Sci. 22, 7836 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"12331_CR27","first-page":"4907","volume":"45","author":"A Rusinko","year":"2004","unstructured":"Rusinko, A., May, J., Liao, J., Namil, A. & Hellberg, M. A study of the enhanced corneal penetration of Moxifloxacin. Invest. Ophthalmol. Vis. Sci. 45, 4907 (2004).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR28","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/mp300305f","volume":"9","author":"RS Kadam","year":"2012","unstructured":"Kadam, R. S., Scheinman, Robert, I. & Kompella, U. B. Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer Blood\u2013Retinal barrier. Mol. Pharm. 9, 3228\u20133235 (2012).","journal-title":"Mol. Pharm."},{"key":"12331_CR29","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ejpb.2012.07.020","volume":"82","author":"E Hellinger","year":"2012","unstructured":"Hellinger, E. et al. Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur. J. Pharm. Biopharm. 82, 340\u2013351 (2012).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"12331_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0021-9258(18)70272-X","volume":"234","author":"RT Schimke","year":"1959","unstructured":"Schimke, R. T. Effects of prolonged light deprivation on the development of retinal enzymes in the rabbit. J. Biol. Chem. 234, 700\u2013703 (1959).","journal-title":"J. Biol. Chem."},{"key":"12331_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/pharmaceutics14010134","volume":"14","author":"M L\u00f6scher","year":"2022","unstructured":"L\u00f6scher, M., Seiz, C., Hurst, J. & Schnichels, S. Topical drug delivery to the posterior segment of the eye. Pharmaceutics 14, 134 (2022).","journal-title":"Pharmaceutics"},{"key":"12331_CR32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/bcp.13794","volume":"85","author":"AM Joussen","year":"2019","unstructured":"Joussen, A. M. et al. The developing regorafenib eye drops for neovascular Age-related macular degeneration (DREAM) study: an open\u2010label phase II trial. Br. J. Clin. Pharmacol. 85, 347\u2013355 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"12331_CR33","doi-asserted-by":"publisher","first-page":"bqad185","DOI":"10.1210\/endocr\/bqad185","volume":"165","author":"JP Robles","year":"2024","unstructured":"Robles, J. P. et al. Vasoinhibin\u2019s apoptotic, inflammatory, and fibrinolytic actions are in a motif different from its antiangiogenic HGR motif. Endocrinology 165, bqad185 (2024).","journal-title":"Endocrinology"},{"key":"12331_CR34","doi-asserted-by":"crossref","unstructured":"Tang, L. H. C. et al. Animal Models of Diabetic Retinopathy (Part 2) in Experimental Animal Models of Human Diseases - An Effective Therapeutic Strategy (ed. Bartholomew, I.) https:\/\/doi.org\/10.5772\/intechopen.70589 (IntechOpen, 2017).","DOI":"10.5772\/intechopen.70589"},{"key":"12331_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ophtha.2014.09.036","volume":"122","author":"KG Csaky","year":"2015","unstructured":"Csaky, K. G. et al. Clinical evaluation of pazopanib eye drops versus Ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology 122, 579\u2013588 (2015).","journal-title":"Ophthalmology"},{"key":"12331_CR36","first-page":"2394","volume":"59","author":"SH Poor","year":"2018","unstructured":"Poor, S. H. et al. Topical VEGF receptor inhibitor, LHA510, did not demonstrate efficacy in a Proof-of-Concept study in patients with neovascular age-related macular degeneration (nv AMD). Invest. Ophthalmol. Vis. Sci. 59, 2394 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nm1534","volume":"13","author":"BB Gao","year":"2007","unstructured":"Gao, B. B. et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat. Med. 13, 181\u2013188 (2007).","journal-title":"Nat. Med."},{"key":"12331_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/157339910793360815","volume":"6","author":"A Praidou","year":"2010","unstructured":"Praidou, A. et al. Angiogenic growth factors and their inhibitors in diabetic retinopathy. Curr. Diabetes Rev. 6, 304\u2013312 (2010).","journal-title":"Curr. Diabetes Rev."},{"key":"12331_CR39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2337\/db06-0427","volume":"56","author":"JA Vincent","year":"2007","unstructured":"Vincent, J. A. & Mohr, S. Inhibition of Caspase-1\/Interleukin-1\u03b2 signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 56, 224\u2013230 (2007).","journal-title":"Diabetes"},{"key":"12331_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nm.3552","volume":"20","author":"K Bajou","year":"2014","unstructured":"Bajou, K. et al. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat. Med. 20, 741\u2013747 (2014).","journal-title":"Nat. Med."},{"key":"12331_CR41","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1530\/EC-18-0116","volume":"7","author":"K Morohoshi","year":"2018","unstructured":"Morohoshi, K., Mochinaga, R., Watanabe, T., Nakajima, R. & Harigaya, T. 16\u00a0kDa vasoinhibin binds to integrin alpha5 beta1 on endothelial cells to induce apoptosis. Endocr. Connect. 7, 630\u2013636 (2018).","journal-title":"Endocr. Connect."},{"key":"12331_CR42","first-page":"2291","volume":"118","author":"C Garcia","year":"2008","unstructured":"Garcia, C. et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J. Clin. Invest. 118, 2291\u20132300 (2008).","journal-title":"J. Clin. Invest."},{"key":"12331_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.addr.2017.12.008","volume":"126","author":"AK Rimpel\u00e4","year":"2018","unstructured":"Rimpel\u00e4, A. K. et al. Implications of melanin binding in ocular drug delivery. Adv. Drug Deliv Rev. 126, 23\u201343 (2018).","journal-title":"Adv. Drug Deliv Rev."},{"key":"12331_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1124\/jpet.118.248427","volume":"366","author":"BC Askew","year":"2018","unstructured":"Askew, B. C., Furuya, T., Edwards, D. S., Edwards, D. & & Ocular distribution and pharmacodynamics of SF0166, a topically administered \u03b1v\u03b23 integrin antagonist, for the treatment of retinal diseases. J. Pharmacol. Exp. Ther. 366, 244\u2013250 (2018).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"12331_CR45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","volume":"57","author":"EM del Amo","year":"2017","unstructured":"del Amo, E. M. et al. Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res. 57, 134\u2013185 (2017).","journal-title":"Prog Retin Eye Res."},{"key":"12331_CR46","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s11095-018-2519-x","volume":"35","author":"GA Rodrigues","year":"2018","unstructured":"Rodrigues, G. A. et al. Topical drug delivery to the posterior segment of the eye: addressing the challenge of preclinical to clinical translation. Pharm. Res. 35, 245 (2018).","journal-title":"Pharm. Res."},{"key":"12331_CR47","first-page":"2498","volume":"40","author":"Z Due\u00f1as","year":"1999","unstructured":"Due\u00f1as, Z. et al. Inhibition of rat corneal angiogenesis by 16-kDa prolactin and by endogenous prolactin-like molecules. Invest. Ophthalmol. Vis. Sci. 40, 2498\u20132505 (1999).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"12331_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","volume":"17","author":"DA Antonetti","year":"2021","unstructured":"Antonetti, D. A., Silva, P. S. & Stitt, A. W. Current Understanding of the molecular and cellular pathology of diabetic retinopathy. Nat. Rev. Endocrinol. 17, 195\u2013206 (2021).","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12331-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12331-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:59:08Z","timestamp":1757275148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12331-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12331"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12331-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JPR, MZ, TB, JT, GME, and CC are inventors of a submitted patent application (WO\/2021\/098996), which is owned by the Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM) and JT. JPR is the CEO and founder of VIAN Therapeutics Inc. MZ and CC are consultants for VIAN Therapeutics. Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26767"}}